1,5-Anhydroglucitol Is Associated with Early-Phase Insulin Secretion in Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus

2015 ◽  
Vol 17 (5) ◽  
pp. 320-326 ◽  
Author(s):  
Xiaojing Ma ◽  
Yaping Hao ◽  
Xiang Hu ◽  
Yuqi Luo ◽  
Zixuan Deng ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Secretion ◽  
Early Phase ◽  
Chinese Patients ◽  
Newly Diagnosed

scholarly journals Association between Triglyceride to HDL-C Ratio (TG/HDL-C) and Insulin Resistance in Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0154345 ◽  
Author(s):  
Xingxing Ren ◽  
Zeng.ai Chen ◽  
Shuang Zheng ◽  
Tingting Han ◽  
Yangxue Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Chinese Patients ◽  
Newly Diagnosed

scholarly journals PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Tao Wang ◽  
Jin-Fang Song ◽  
Xue-Yan Zhou ◽  
Cheng-Lin Li ◽  
Xiao-Xing Yin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Plasma Glucose ◽  
Therapeutic Efficacy ◽  
Chinese Patients ◽  
Model Assessment ◽  
Newly Diagnosed ◽  
Homeostasis Model Assessment

Abstract Background Genetic polymorphisms in the PPARD and NOS1AP is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide. This study was designed to investigate a potential association of PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms with efficacy of nateglinide in newly diagnosed Chinese patients with type 2 diabetes mellitus (T2DM). Methods Sixty patients with newly diagnosed T2DM were enrolled to identify PPARD rs2016520 and NOS1AP rs12742393 genotypes using the polymerase chain reaction-restriction fragment length polymorphism assay (PCR–RFLP). All subjects were treated with nateglinide (360 mg/day) for 8 weeks. Anthropometric measurements, clinical laboratory tests were obtained at baseline and after 8 weeks of nateglinide treatment. Results After nateglinide treatment for 8 consecutive weeks, patients with at least one C allele of PPARD rs2016520 showed a smaller decrease in post plasma glucose (PPG), homeostasis model assessment for beta cell function (HOMA-B) than those with the TT genotype did (P < 0.05). In patients with the AA genotype of NOS1AP rs12742393, the drug showed better efficacy with respect to levels of fasting plasma glucose (FPG), fasting serum insulin (FINS), HOMA-B and homeostasis model assessment for insulin resistance (HOMA-IR) than in patients with the AC + CC genotype (P < 0.05). NOS1AP rs12742393 genotype distribution and allele frequency were associated with responsiveness of nateglinide treatment (P < 0.05). Conclusions The PPARD rs2016520 and NOS1AP rs12742393 polymorphisms were associated with nateglinide monotherapy efficacy in Chinese patients with newly diagnosed T2DM. Trial registration Chinese Clinical Trial Register ChiCTR13003536, date of registration: May 14, 2013.

scholarly journals Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus

2001 ◽  
Vol 86 (12) ◽  
pp. 5824-5829 ◽  
Author(s):  
Steven E. Kahn ◽  
Brenda Montgomery ◽  
William Howell ◽  
Monica Ligueros-Saylan ◽  
Chyi-Hung Hsu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Secretion ◽  
Glucose Tolerance ◽  
Early Phase ◽  
Intravenous Glucose ◽  
Intravenous Glucose Tolerance
Sign in / Sign up

Export Citation Format

Share Document